<DOC>
	<DOCNO>NCT01063816</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose veliparib ( ABT-888 ) establish recommend Phase 2 dose veliparib ( ABT-888 ) administer combination carboplatin gemcitabine subject advance solid tumor .</brief_summary>
	<brief_title>A Study ABT-888 Combination With Carboplatin Gemcitabine Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor metastatic unrespectable carboplatin/gemcitabine treatment option . Eastern Cooperative Group performance score 0 2 . Adequate hematologic , hepatic renal function Subject receive 2 DNA damage cytotoxic regimen past five year Subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , biologic investigational therapy within 28 day prior study administration . Subjects know history brain metastasis primary CNS tumor . Hypersensitivity reaction platinum compound gemcitabine . Clinically significant uncontrolled major medical condition Active malignancy within past 5 year except cancer situ cure nonmelanoma carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PARP Inhibitors</keyword>
</DOC>